The most frequent of these immune-mediated toxicities are cytokine release syndrome (CRS) and immune effector ... Jain ...
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...